Follow on Google News News By Tag * Hiv * Treatment * Pipeline * Drug * Gene * Monoclonal * Clinical * Trial * Novel * Pre-exposure * More Tags... News By Place Country(s) Industry News
Follow on Google News | "R&D Trends: HIV - An active pipeline faces fierce competition in the HIV market" PublishedNew Healthcare market report from Datamonitor: "R&D Trends: HIV - An active pipeline faces fierce competition in the HIV market"
By: Health, Medical, Research Although there are a number of novel approaches in early-stage development for HIV, fierce competition is thinning out the late-stage pipeline. Novel treatment approaches, biomedical HIV prevention and genetic profiling could diversify an HIV market currently dominated by a one-pill once-daily regimen. Features and benefits * Overview of the HIV late-and early-stage pipeline and potential drug targets. * Examination of innovative treatment approaches, such as vaccines, monoclonal antibodies and gene therapy * Identification of the target product profile for novel HIV treatments * Discussion of the future of HIV treatment and trends towards personalized HAART Highlights Datamonitor believes that the foreseeable future of HIV treatment will be defined by earlier treatment initiation, further progress in the field of pre-exposure prophylaxis and a HIV market driven by convenience and patients' individual preferences Monoclonal antibodies and gene treatments are among the most innovative approaches in the HIV pipeline. Progenics' Pro-140 recently entered Phase IIb clinical trials, making it the furthest advanced monoclonal antibody against HIV. In contrast, novel gene therapies deliver first promising results, but are still in very early stages of development The majority of pipeline drugs can be classified according to the historical HIV drug classes, but several innovative treatment approaches promise to extend future HIV treatment options ------------------------------------------------------------ Full Report Details at - http://www.fastmr.com/ ------------------------------------------------------------ Your key questions answered * Understand current trends in HIV drug development and HIV prevention and learn about key factors set to shape the field in the future * Understand challenges, unmet needs and future opportunities by learning about the views of HIV key opinion leaders * Review the late- and early-stage HIV pipeline and explore innovative approaches in HIV treatment Report Table of Contents: Executive Summary Strategic scoping and focus Datamonitor key findings Related reports OVERVIEW Catalyst Summary CLINICAL PIPELINE OVERVIEW Key findings Pipeline overview Only seven compounds are currently in Phase III/registration Drugmakers are seeking to co-formulate their lead HIV pipeline candidates into cross-class fixed-dose combinations Entry inhibitors dominate the early- and mid-stage pipeline Several pipeline agents are developed as non-oral formulations Therapeutic vaccines - an alternative to HAART? HIV lifecycle and mechanism of action of HIV drug classes The HIV lifecycle offers diverse targets for antiretroviral drugs Mechanism of action of currently available anti-HIV drugs Late-stage development compounds recently discontinued In 2010, two Phase III drugs fell victim to the increasing competition in the HIV market space TARGET PRODUCT PROFILE Key findings Atripla (tenofovir disoproxil fumarate/emtricitabine/ Target product profile versus current level of attainment CLINICAL TRIAL DESIGN IN HIV Key findings Trial design for treatment-naive and treatment-experienced patients Non-inferiority trials are the standard design for HIV drug development Choice of control arms Background regimens Duration of studies Clinical trial endpoints Future developments in clinical trial design INNOVATIVE EARLY-STAGE APPROACHES Key findings Monoclonal antibodies and gene treatments as novel HIV therapeutics Progenics's Pro-140 is the lead candidate among anti-HIV monoclonal antibodies Gene therapy for the treatment of HIV is still in its infancy but excites with early successes 2010 was a milestone year for biomedical HIV prevention Truvada as oral pre-exposure prophylaxis in men having sex with men HIV microbicides: Vaccines for the prevention of HIV THE FUTURE OF TREATMENT IN HIV Key findings Earlier initiation of HIV treatment Disagreement in US and EU HIV treatment guidelines about treatment initiation thresholds continues Pre-exposure prophylaxis Greater use of genetic profiling BIBLIOGRAPHY Journal papers Websites Datamonitor reports APPENDIX Contributing experts Conferences attended Report methodology About Datamonitor The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at http://www.fastmr.com/ About Fast Market Research Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156. # # # Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|